Gritstone Earns 2022 Great Place to Work Certification™
June 02 2022 - 8:00AM
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology
company that aims to develop the world’s most potent vaccines,
today announced that the company has been certified as a Great
Place to Work by the Great Place to Work® Institute. Gritstone
earned this highly desirable credential based on a comprehensive
set of ratings provided by its employees in an anonymous survey.
The award is based entirely on what current employees say about
their experience working at Gritstone bio.
“We are very proud to receive the designation as a Great Place
to Work,” said Andrew Allen, M.D., Ph.D., Co-founder, President and
Chief Executive Officer of Gritstone. “As a fully integrated
vaccine discovery, development and manufacturing company, our
employees span a variety of functions and worksites and to
understand that they collectively find Gritstone a great place to
work, which enabled this award, speaks to the depth of our mission
and culture. We are committed to enabling our employees to
contribute, grow, and flourish while on our journey to improve
patient outcomes and eliminate disease.”
Great Place to Work® is the global authority on workplace
culture, employee experience, and the leadership behaviors proven
to deliver market-leading revenue, employee retention and increased
innovation.
Stacy Proctor, Senior Vice President and Head of People of
Gritstone, added, “Gritstone employees are amazing and passionate
people who continually reinforce trust and camaraderie across the
Gritstone organization. This recognition acknowledges the inclusive
and rewarding work environment, culture, and pride of working at
Gritstone.”
To learn more about Gritstone’s culture and job opportunities,
visit https://gritstonebio.com/career-opportunities/
About Great Place to Work Certification™Great
Place to Work® Certification™ is the most definitive
“employer-of-choice” recognition that companies aspire to achieve.
It is the only recognition based entirely on what employees report
about their workplace experience – specifically, how consistently
they experience a high-trust workplace. Great Place to Work
Certification is recognized worldwide by employees and employers
alike and is the global benchmark for identifying and recognizing
outstanding employee experience. Every year, more than 10,000
companies across 60 countries apply to get Great Place to
Work-Certified.
About Gritstone Gritstone bio, Inc. (Nasdaq:
GRTS) is a clinical-stage biotechnology company that aims to create
the world’s most potent vaccines. We leverage our innovative
vectors and payloads to train multiple arms of the immune system to
attack critical disease targets. Independently and with our
collaborators, we are advancing a portfolio of product candidates
to treat and prevent viral diseases and solid tumors in pursuit of
improving patient outcomes and eliminating disease.
www.gritstonebio.com
Gritstone Forward-Looking
StatementsThis press release contains
forward-looking statements, including, but not limited to,
statements related to the potential of Gritstone’s therapeutic
programs; the advancements in the company’s ongoing clinical
trials; the timing of data announcements related to ongoing
clinical trials and the initiation of future clinical trials. Such
forward-looking statements involve substantial risks and
uncertainties that could cause Gritstone’s research and clinical
development programs, future results, performance or achievements
to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the uncertainties inherent in the drug development
process, including Gritstone’s programs’ early stage of
development, the process of designing and conducting preclinical
and clinical trials, the regulatory approval processes, the timing
of regulatory filings, the challenges associated with manufacturing
drug products, Gritstone’s ability to successfully establish,
protect and defend its intellectual property and other matters that
could affect the sufficiency of existing cash to fund operations.
Gritstone undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of the company in general, see
Gritstone’s most recent Quarterly Report on Form 10-Q filed on May
5, 2022 and any current and periodic reports filed with the
Securities and Exchange Commission.
Gritstone ContactsMedia:Dan Budwick1AB(973)
271-6085dan@1abmedia.com
Investors:George E. MacDougallDirector, Investor Relations &
Corp CommsGritstone bio, Inc.IR@gritstone.com
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Jul 2023 to Jul 2024